Molecular histological characteristics of breast tumors for women from the Kyrgyz population - the contribution of the genes TP53, XRCC1 and MDM2

The study included 100 women of the Kyrgyz ethnic group with the morphologically verified diagnosis of breast cancer (BC) from National cancer center of Bishkek (Kyrgyz Republic) in the period 2013-2015 years. The average age of patients with breast cancer was 47,6 ± 10,0 years (age interval is 23,5-74,1 years). Genotyping of single-nucleotide polymorphisms (SNPs) p.Q399R ( XRCC1 ), p.R194W ( XRCC1 ), p.P72R ( TP53 ) and c.309T>G ( MDM2 ) was performed using PCR-RFLP. Comparison of results of the analysis of genotyping and morphological characteristics of a tumor node in the examined subgroups used the Fisher’s exact test. For comparison of quantitative data after checking for homoscedasticity and the normality of distribution using the method of variance analysis ANOVA. Statistical data processing was performed using Microsoft Excel (Microsoft Corporation, USA) and SPSS v.20.0 (IBM, USA). For SNPs p.P72R ( TP53 ) and p.R194W ( XRCC1 ) there are a statistically significant association with age verification of diagnosis of breast cancer. For 78,0% (71/91) of the patients with genotype CG/GG for SNP p.P72R ( TP53 ) was diagnosed to 55 years, for 55,6% (5/9) of the patients with genotype CC was diagnosed after 55 years, p = 0,041. For the polymorphism p.R194W ( XRCC1 ) were shown statistically significant association with age verification of diagnosis of breast cancer: for patients with genotype CC of the calculated value made up of 46,12 ± 10,21 years, for patients with genotypes TT/CT - of 50,98 ± 8,70, p = 0,024. At the same time, multivariate analysis of variance no showed relationship between age verification of breast cancer diagnosis and genotyping data at the SNPs p.Q399R ( XRCC1 ), p.R194W ( XRCC1 ), p.P72R ( TP53 ) and c.309T>G ( MDM2 ). Also revealed no statistically significant differences between the results of genotyping and histological type of the tumor, the values of the TNM-classification and the degree of differentiation of the tumor.

рак молочной железы, ген, XRCC1, TP53, MDM2, ПЦР-ПДРФ, полиморфизм, кыргызская популяция, breast cancer, gene, XRCC1, TP53, MDM2, PCR-RFLP, polymorphism, kyrgyz population

1. Dizdaroglu M. Oxidatively induced DNA damage and its repair in cancer. Mutation Research - Reviews. 2015 Jan-Mar;763:212-45.

2. Panda PK, Mukhopadhyay S, Das DN,et al. Mechanism of autophagic regulation in carcinogenesis and cancer therapeutics. Semin Cell Dev Biol. 2015 Mar;39:43-55.

3. Roberts MR, Shields PG, Ambrosone CB, et al. Single-nucleotide polymorphisms in DNA repair genes and association with breast cancer risk in the web study. Carcinogenesis. 2011 Aug;32(8):1223-30.

4. Travis RC, Reeves GK, Green J, et al. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet. 2010 Jun 19;375(9732):2143-51.

5. Абдылдаев ДК. Клиническое руководство по клиническому обследованию молочной железы для медицинских специалистов первичного уровня здравоохранения, принятого Экспертным советом по оценке качества клинических руководств/протоколов. Утверждено Приказом МЗ КО 34348 от 6 сентября 2010 г., Бишкек, 2010.

6. Sanjari Moghaddam A, Nazarzadeh M, Bidel Z, et al. XRCC1 Gene Polymorphisms and Breast Cancer Risk: A Systematic Review and Meta- Analysis Study. Asian Pac J Cancer Prev. 2016;17 Spec No.:323-30.

7. Исакова ЖТ, Талайбекова ЭТ, Макиева КБ, и др. Ассоциация полиморфных маркеров Arg399Gln гена XRCC1, Arg72Pro гена TP53 и T309G гена MDM2 с раком молочной железы у женщин кыргызской популяции. Российский онкологический журнал. 2016. Т. 21. № 3. С. 131-135.

8. Demokan S, Demir D, Suoglu Y, et al. Polymorphisms of the XRCC1 DNA repair gene in head and neck cancer. Pathol Oncol Res. 2005;11(1):22-5.

9. Upton GJG, Fisher’s exact test //Journal of the Royal Statistical Society. Series A (Statistics in Society). 1992. P. 395-402;

10. Roberts MR, Shields PG, Ambrosone CB, et al. Single-nucleotide polymorphisms in DNA repair genes and association with breast cancer risk in the web study. Carcinogenesis. 2011. P.1223-1230;

11. Sangrajrang S, Schmezer P, Burkholder I, et al. The XRCC3 Thr241Met polymorphism and breast cancer risk: a case-control study in a Thai population. Biomarkers. 2007. P.523-532;

12. Cherdyntseva NV, Denisov EV, Litviakov NV, et al. Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis. DNA Cell Biol. 2012. P.306-316;

13. Yoshimoto N, Nishiyama T, Toyama T, et al. Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women. Cancer Sci. 2011. P.2065-2072;

14. Denisov EV, Cherdyntseva NV, Litvyakov NV, et al. TP53 mutations and Arg72Pro polymorphism in breast cancers. Cancer Genet Cytogenet. 2009 Jul 15;192(2):93-5.

15. Кипень ВН, Снытков ЕВ, Мельнов СБ. Молекулярно-гистологическая характеристика опухолей молочной железы - вклад генов HMMR и TP53. Молодежь в науке - 2014. Приложение к журналу «Весці Нацыянальнай акадэміі навук Беларусі». 2014. с.43-46.

16. Stuckey AR, Onstad MA. Hereditary breast cancer: an update on risk assessment and genetic testing in 2015. Am J Obstet Gynecol. 2015 Aug;213(2):161-5.

17. International Statistical Classification of Diseases and Related Health Problems 10th Revision. Edition 2010. 1v - 3 v.

18. Tao Z, Shi A, Lu C, et al. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys. 2015 Jun;72(2):333-8.

19. Tommiska J, Eerola H, Heinonen M, et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res. 2005 Jul 15;11(14):5098-103.

20. Romanowicz-Makowska H, Smolarz B, Zadrozny M, et al. Single nucleotide polymorphisms in the homologous recombination repair genes and breast cancer risk in Polish women. Tohoku J Exp Med. 2011;224(3):201-8.